Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.

Papadimitriou K, Kountourakis P, Morakis E, Vassiliou V, Barbounis V, Ardavanis A.

Case Rep Med. 2012;2012:810428. doi: 10.1155/2012/810428. Epub 2012 Apr 11.

2.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
3.

Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?

Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.

Clin Breast Cancer. 2009 Feb;9(1):34-8. doi: 10.3816/CBC.2009.n.006.

PMID:
19299238
5.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
6.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
7.
8.

Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.

Moegele M, Buchholz S, Seitz S, Ortmann O.

Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. Review.

PMID:
22212649
9.
10.

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.

Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C.

Breast Cancer Res Treat. 2010 Feb;120(1):127-34. doi: 10.1007/s10549-009-0692-7. Epub 2009 Dec 25.

PMID:
20035381
11.

Exemestane: a review of its use in postmenopausal women with breast cancer.

Deeks ED, Scott LJ.

Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Review.

PMID:
19441873
12.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

13.

Aromatase inhibitor-associated arthralgia syndrome.

Burstein HJ.

Breast. 2007 Jun;16(3):223-34. Epub 2007 Mar 21. Review.

PMID:
17368903
14.

The role of aromatase inhibitors in the treatment of metastatic breast cancer.

Mouridsen H, Gershanovich M.

Semin Oncol. 2003 Aug;30(4 Suppl 14):33-45. Review.

PMID:
14513435
15.
16.

Role of aromatase inhibitors in the treatment of breast cancer.

Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT.

Clin Ther. 2004 Aug;26(8):1199-214. Review.

PMID:
15476902
17.
18.
19.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87. Epub 2005 Jul 5.

20.

Exemestane in postmenopausal women with early or advanced breast cancer: a review.

Bertelli G, Gangadhara S.

Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945. Review.

PMID:
20569090
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk